The global infectious disease therapeutics Market is estimated to be valued at US$ 170.67 Bn or Billion in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
The infectious disease therapeutics market comprises products such as antibiotics, antivirals, antifungals and others used to treat infectious diseases caused by bacteria, viruses, fungi and parasites. Antibiotics treat bacterial infections more effectively and prevent emergence of drug resistance by killing or inhibiting the growth of bacteria.

Market key trends:
One of the key trends in the infectious disease therapeutics market is the development and commercialization of novel broad spectrum antibiotics. With many bacteria developing resistance to front line antibiotics, there is an urgent need to develop new classes of antibiotics that can effectively treat drug-resistant infections. Many pharmaceutical companies are investing heavily in antimicrobial resistance research to develop novel broad spectrum antibiotics that work through new mechanisms of action and can treat multi-drug resistant pathogens. These efforts are expected to boost the sales of new antibiotics over the forecast period.

Segment Analysis
The global infectious disease therapeutics market is segmented based on disease type, therapeutics, distribution channel, and region. Based on disease type, the market is segmented into bacterial disease, viral disease, parasitic disease and fungal disease. The viral disease segment dominated the market in 2022 due to high prevalence of viral infections such as hepatitis, HIV/AIDS, influenza etc. worldwide. Based on therapeutics, the market is segmented into antiviral drugs, anti-parasitic drugs, anti-bacterial drugs and anti-fungal drugs. The antiviral drugs segment accounted for the largest market share in 2022 owing to rising demand for antiviral therapies for diseases like hepatitis, HIV and influenza.

Key Takeaways
The Global Infectious Disease Therapeutics Market Size is expected to witness high growth, exhibiting CAGR Of 3.7% over the forecast period, due to increasing prevalence of infectious diseases worldwide. The global infectious disease therapeutics market size for 2023 is US$ 170.67 Bn.

Regional analysis: North America dominated the global market in 2022 owing to rising R&D investments by key players, growing prevalence of infectious diseases and availability of advanced healthcare facilities in the region. Asia Pacific is anticipated to exhibit fastest growth over the forecast period attributed to increasing healthcare expenditure, large patient pool and growth of generic drugs market in emerging economies like India and China.

Key players: Key players operating in the infectious disease therapeutics market are Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), Merck & Co. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca (U.K), Mylan N.V. (U.S.), Novartis AG (Switzerland), Sanofi (France). These players are focusing on new product launches, mergers & acquisitions and geographic expansion to strengthen their market presence globally.

Read more https://journaljourney32.weebly.com/therapeutics-market